Current perspectives and trend of nanomedicine in cancer: a review and bibliometric analysis

Z Pei, S Chen, L Ding, J Liu, X Cui, F Li, F Qiu - Journal of Controlled …, 2022 - Elsevier
The limitations of traditional cancer treatments are driving the creation and development of
new nanomedicines. At present, with the rapid increase of research on nanomedicine in the …

[HTML][HTML] Targeting of CD163+ Macrophages in Inflammatory and Malignant Diseases

MK Skytthe, JH Graversen, SK Moestrup - International journal of …, 2020 - mdpi.com
The macrophage is a key cell in the pro-and anti-inflammatory response including that of the
inflammatory microenvironment of malignant tumors. Much current drug development in …

[HTML][HTML] Sex-specific differences in glioblastoma

A Carrano, JJ Juarez, D Incontri, A Ibarra, HG Cazares - Cells, 2021 - mdpi.com
Sex differences have been well identified in many brain tumors. Even though glioblastoma
(GBM) is the most common primary malignant brain tumor in adults and has the worst …

IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM

M Zannikou, JT Duffy, RN Levine… - Journal for …, 2023 - pmc.ncbi.nlm.nih.gov
Introduction The immunosuppressive tumor microenvironment (TME) is a major barrier to the
efficacy of chimeric antigen receptor T cells (CAR-T cells) in glioblastoma (GBM). Transgenic …

Next-generation antigen-presenting cell immune therapeutics for gliomas

C Lee-Chang, MS Lesniak - The Journal of clinical investigation, 2023 - jci.org
Antigen presentation machinery and professional antigen-presenting cells (APCs) are
fundamental for an efficacious immune response against cancers, especially in the context …